Page last updated: 2024-08-03 23:11:19
m8-nelfinavir
Description
M8-nelfinavir: structure in first source [MeSH]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 75213036 |
| MeSH ID | M0507663 |
Synonyms (1)
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 3 (42.86%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (57.14%) | 84.16% |
Evaluation of Elisa test for therapeutic monitoring of Nelfinavir in HIV-positive patients.The new microbiologica, , Volume: 30, Issue:3, 2007
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavirJournal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Jan-01, Volume: 845, Issue:1, 2007
The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.Molecules (Basel, Switzerland), , Jan-12, Volume: 17, Issue:1, 2012
Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection: the VIRAKINETICS II study.Current HIV research, , Volume: 7, Issue:3, 2009
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.British journal of clinical pharmacology, , Volume: 65, Issue:4, 2008
Evaluation of Elisa test for therapeutic monitoring of Nelfinavir in HIV-positive patients.The new microbiologica, , Volume: 30, Issue:3, 2007
The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.Molecules (Basel, Switzerland), , Jan-12, Volume: 17, Issue:1, 2012
Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection: the VIRAKINETICS II study.Current HIV research, , Volume: 7, Issue:3, 2009
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.British journal of clinical pharmacology, , Volume: 65, Issue:4, 2008
Evaluation of Elisa test for therapeutic monitoring of Nelfinavir in HIV-positive patients.The new microbiologica, , Volume: 30, Issue:3, 2007
Pharmacokinetics (3)
| Article | Year |
|---|
Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum.
Journal of clinical pharmacology, , Volume: 59, Issue:3 | 2019 |
The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.
Molecules (Basel, Switzerland), , Jan-12, Volume: 17, Issue:1 | 2012 |
Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.
British journal of clinical pharmacology, , Volume: 68, Issue:5 | 2009 |
Bioavailability (1)